AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Identification of C3 complement molecule at the site of injury to blood vessels in the retina of oxygen exposed newborn mice

Summary: John T. Flynn, M.D.

Technology Benefits: This is an alternative treatment for ROP. Current treatments are invasive surgeries on the eye, with no information on the long-term effects. Patent information:Patent Pending (WO/2012/118833)

Technology Application: Method for treating, preventing, or reducing oxygen damage in ROPNew Information regarding the underlying cause of ROP will lead to:Better treatment protocols at Neonatal Intensive Care Units (NICUs) to prevent ROPIdentification of additional risk factor(s)Development of drug therapy

Detailed Technology Description: John T. Flynn, M.D.

*Abstract: None

*Inquiry: Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR: 2703

*Principal Investigator

*Publications: M.F. Chiang, R. Gelman, M.E. Martinez-Perez, Y.E. Du, D.S.Casper, L.M. Currie, P.D. Shah, J. Starren, J.T. Flynn. Image analysis for retinopathy of prematurity diagnosis. Journal of American Association for Pediatric Opthalmology and Strabismus, Vol 13, Issue 5, Oct. 2009, pp. 438-445.

Country/Region: USA

For more information, please click Here